S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

HCW Biologics Stock Forecast, Price & News

-0.15 (-5.23%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
58,111 shs
Average Volume
2.08 million shs
Market Capitalization
$97.18 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive HCWB News and Ratings via Email

Sign-up to receive the latest news and ratings for HCW Biologics and its competitors with MarketBeat's FREE daily newsletter.

HCW Biologics logo

About HCW Biologics

HCW Biologics Inc. is a preclinical stage biopharmaceutical company. It focused on discovering and developing novel immunotherapies. HCW Biologics Inc. is based in MIRAMAR, Fla.


See More Headlines

Industry, Sector and Symbol

Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Market Cap
$97.18 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1379th out of 1,392 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

HCW Biologics (NASDAQ:HCWB) Frequently Asked Questions

Are investors shorting HCW Biologics?

HCW Biologics saw a decrease in short interest in November. As of November 15th, there was short interest totaling 94,100 shares, a decrease of 39.4% from the October 31st total of 155,400 shares. Based on an average trading volume of 2,960,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.8% of the company's stock are sold short.
View HCW Biologics' Short Interest

When is HCW Biologics' next earnings date?

HCW Biologics is scheduled to release its next quarterly earnings announcement on Friday, February 11th 2022.
View our earnings forecast for HCW Biologics

How were HCW Biologics' earnings last quarter?

HCW Biologics Inc (NASDAQ:HCWB) issued its quarterly earnings data on Friday, November, 12th. The company reported ($0.63) earnings per share (EPS) for the quarter.
View HCW Biologics' earnings history

When did HCW Biologics IPO?

(HCWB) raised $45 million in an IPO on Tuesday, July 20th 2021. The company issued 5,600,000 shares at $8.00 per share. EF Hutton acted as the underwriter for the IPO and Revere Securities was co-manager.

What is HCW Biologics' stock symbol?

HCW Biologics trades on the NASDAQ under the ticker symbol "HCWB."

When does the company's lock-up period expire?

HCW Biologics' lock-up period expires on Monday, January 17th. HCW Biologics had issued 7,000,000 shares in its initial public offering on July 20th. The total size of the offering was $56,000,000 based on an initial share price of $8.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Who are HCW Biologics' major shareholders?

HCW Biologics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.13%), UBS Group AG (0.10%), Geode Capital Management LLC (0.06%), Goldman Sachs Group Inc. (0.06%) and HighTower Advisors LLC (0.04%).

Which institutional investors are buying HCW Biologics stock?

HCWB stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, UBS Group AG, Geode Capital Management LLC, Goldman Sachs Group Inc., and HighTower Advisors LLC.

How do I buy shares of HCW Biologics?

Shares of HCWB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HCW Biologics' stock price today?

One share of HCWB stock can currently be purchased for approximately $2.72.

How much money does HCW Biologics make?

HCW Biologics has a market capitalization of $97.18 million.

How many employees does HCW Biologics have?

HCW Biologics employs 40 workers across the globe.

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.